Global Liraglutide Market Growth 2023-2029

Global Liraglutide Market Growth 2023-2029

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.

LPI (LP Information)' newest research report, the “Liraglutide Industry Forecast” looks at past sales and reviews total world Liraglutide sales in 2022, providing a comprehensive analysis by region and market sector of projected Liraglutide sales for 2023 through 2029. With Liraglutide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liraglutide industry.

This Insight Report provides a comprehensive analysis of the global Liraglutide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liraglutide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Liraglutide market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liraglutide and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liraglutide.

The global Liraglutide market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Liraglutide is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Liraglutide is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Liraglutide is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Liraglutide players cover HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide and AmbioPharm, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Liraglutide market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Pills

Liquid

Segmentation by application

Hospital

Drug Store

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

HEC Pharm

Bachem

Bharat Pharmaceuticals

Kingpep Biotechnology

Shenzhen JYMed Technology

Wuxi Asiapeptide

AmbioPharm

Key Questions Addressed in this Report

What is the 10-year outlook for the global Liraglutide market?

What factors are driving Liraglutide market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Liraglutide market opportunities vary by end market size?

How does Liraglutide break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.